Cover Image
市場調查報告書

血脂異常:開發平台分析

Dyslipidemia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232789
出版日期 內容資訊 英文 291 Pages
訂單完成後即時交付
價格
Back to Top
血脂異常:開發平台分析 Dyslipidemia - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 291 Pages
簡介

所謂血脂異常症,是血中的整體膽固醇值上升,或是「壞」低密度脂蛋白(LDL)膽固醇與三酸甘油酯(中性脂肪)增加,「好」高密度脂蛋白(HDL)膽固醇濃度下降的狀態。由於各式各樣的因素與原因,使血液中的脂質濃度發生異常。譬如,遺傳性原因、伙食、年齡和性、第二型糖尿病等。 血脂異常引起的一般症狀,有角膜混濁、角膜環、黃色瘤、平衡障礙、步行時小腿疼痛、暈眩等。

本報告提供血脂異常症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關的開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新新聞和發表。

簡介

  • 調查範圍

血脂異常症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發作的企業

  • Acasti Pharma Inc.
  • Allergan Plc
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arbutus Biopharma Corporation
  • Arisaph Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • AtheroNova Inc.
  • BASF SE
  • BCWorld Pharm Co. Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cardax Pharmaceuticals, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • Chong Kun Dang Pharmaceutical Corp.
  • CJ HealthCare Corp.
  • Connexios Life Sciences Pvt. Ltd.
  • CymaBay Therapeutics, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • 第一三共
  • Debiopharm International S.A.
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • Genfit SA
  • GlaxoSmithKline Plc
  • HanAll Biopharma Co., Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Huons Co., Ltd.
  • Hyundai Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • IPCA Laboratories Limited
  • Jeil Pharmaceutical Co., Ltd.
  • Jenrin Discovery, Inc.
  • JW Pharmaceutical Corporation
  • Kissei藥品工業
  • 祝詞製藥
  • 興和
  • Kymab Limited
  • LG Life Science LTD.
  • Lipicard Technologies Limited
  • Lotus Pharmaceutical Co., Ltd.
  • Matinas BioPharma Holdings, Inc.
  • Merck & Co., Inc.
  • Nimbus Therapeutics, LLC
  • Nippon Chemipher
  • Pfizer Inc.
  • Pharmena SA
  • Prometheon Pharma, LLC
  • Protalix BioTherapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sancilio & Company, Inc.
  • 武田藥品工業
  • Thetis Pharmaceuticals LLC
  • Torrent Pharmaceuticals Limited
  • Viking Therapeutics, Inc.
  • Yuhan Corporation
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (amlodipine besylate + atorvastatin calcium + valsartan)
  • (amlodipine besylate + rosuvastatin calcium + valsartan)
  • (atorvastatin calcium + choline fenofibrate)
  • (atorvastatin calcium + hydroxychloroquine sulfate)
  • (atorvastatin calcium + losartan potassium)
  • (atorvastatin calcium + metformin hydrochloride) XR
  • (candesartan + rosuvastatin calcium)
  • (ezetimibe + rosuvastatin calcium)
  • (gemigliptin + rosuvastatin calcium)
  • (metformin hydrochloride SR + rosuvastatin calcium)
  • (pitavastatin + valsartan)
  • 4655-K09
  • AEM-28
  • AEM-2802
  • AEM-2814
  • AHRO-001
  • ALN-AC3
  • ALN-ANG
  • AMG-899
  • anacetrapib
  • ARI-3037MO
  • AS-1708727
  • AZ-12260493
  • BCWPC-001
  • bempedoic acid
  • bezafibrate ER
  • BH-03004
  • BioE-1115
  • bococizumab
  • BSN-272
  • C-24
  • C-3
  • CAT-2000 系列
  • CAT-2003
  • CDR-267F018
  • CDX-085
  • centatin
  • CER-209
  • CKD-519
  • CNX-013B2
  • Debio-0930B
  • DF-461
  • DPR-212
  • DS-8312
  • DS-9001
  • DWJ-1330
  • DWJ-1351
  • elafibranor
  • etanercept biosimilar
  • gemcabene calcium
  • GSK-2041706
  • HCP-1105
  • HOB-071
  • HU-012
  • IBI-306
  • icosabutate
  • IONIS-ANGPTL3LRx
  • ISIS-APOCIIILRx
  • JD-2000 系列
  • JD-5000 系列
  • JD-5006
  • JD-5037
  • JD-6000 系列
  • JLP-1302
  • JLP-1401
  • K-312
  • K-877
  • KT-6971
  • KTA-439
  • KY-1020
  • 白氨酸 + Niacin
  • LP-071
  • LT-5421
  • LT-5423
  • MAT-9001
  • MBX-8025
  • NC-2400
  • ND-630
  • ND-654
  • NKPL-66
  • 血脂異常症、動脈粥狀硬化性心血管疾病用寡核苷酸
  • 歐米加-3-羧酸
  • peroxibrate
  • PF-06427878
  • PF-06815345
  • pitabasutachin CR
  • 血脂異常症用HMG-CoA 還原酵素阻礙蛋白質
  • 血脂異常症用組換形式ApoE4
  • REGN-1001
  • saroglitazar
  • SC-401
  • 肥胖、血脂異常症、第二型糖尿病用Diacylglycerol Acyltransferase抑制劑1
  • 肥胖、血脂異常症、第二型糖尿病用Diacylglycerol Acyltransferase抑制劑2
  • 血脂異常症用小分子
  • 高甘油三酯血症用小分子
  • 第二型糖尿病、血脂異常症用小分子
  • 血脂異常症用脂蛋白解脂酵素活性小分子
  • 血脂異常症用甲狀腺荷爾蒙受體β 促效劑
  • 血脂異常症用farunesoidoX受體拮抗劑
  • 代謝障礙TRIP-Br2 抑制劑
  • 血脂異常症用、用高甘油三酯血症小分子
  • 血脂異常症、肥胖症用 DGAT-1抑制劑
  • 血脂異常症用 內皮層解脂酵素抑制劑
  • SPX-100
  • SPX-8522876
  • 循環系統疾病、消化疾病、代謝障礙、感染疾病用合成肽
  • TKMApoC-3
  • TP-101
  • TP-452
  • TRC-210258
  • TRIA-662
  • VK-0214
  • VK-2809
  • volanesorsen sodium
  • YH-22189
  • ZLN-005
  • ZLN-024
  • ZYH-7

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9649IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H2 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 22, 18, 13, 4, 46 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 5 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Dyslipidemia - Overview
  • Dyslipidemia - Therapeutics Development
  • Dyslipidemia - Therapeutics Assessment
  • Dyslipidemia - Companies Involved in Therapeutics Development
  • Dyslipidemia - Drug Profiles
  • Dyslipidemia - Dormant Projects
  • Dyslipidemia - Discontinued Products
  • Dyslipidemia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Dyslipidemia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Dyslipidemia - Pipeline by Acasti Pharma Inc, H2 2017
  • Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H2 2017
  • Dyslipidemia - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
  • Dyslipidemia - Pipeline by Amgen Inc, H2 2017
  • Dyslipidemia - Pipeline by AstraZeneca Plc, H2 2017
  • Dyslipidemia - Pipeline by BASF SE, H2 2017
  • Dyslipidemia - Pipeline by BCWorld Pharm Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Bioleaders Corp, H2 2017
  • Dyslipidemia - Pipeline by BioRestorative Therapies Inc, H2 2017
  • Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd, H2 2017
  • Dyslipidemia - Pipeline by Cardax Inc, H2 2017
  • Dyslipidemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2017
  • Dyslipidemia - Pipeline by Celon Pharma SA, H2 2017
  • Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H2 2017
  • Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Dyslipidemia - Pipeline by CJ HealthCare Corp, H2 2017
  • Dyslipidemia - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017
  • Dyslipidemia - Pipeline by CymaBay Therapeutics Inc, H2 2017
  • Dyslipidemia - Pipeline by Daewon Pharm Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Dyslipidemia - Pipeline by Eli Lilly and Company, H2 2017
  • Dyslipidemia - Pipeline by Esperion Therapeutics Inc, H2 2017
  • Dyslipidemia - Pipeline by Gemphire Therapeutics Inc, H2 2017
  • Dyslipidemia - Pipeline by Gilead Sciences Inc, H2 2017
  • Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Dyslipidemia - Pipeline by Golden Biotechnology Corp, H2 2017
  • Dyslipidemia - Pipeline by HanAll Biopharma Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Handok Inc, H2 2017
  • Dyslipidemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Huons Global Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Innovent Biologics Inc, H2 2017
  • Dyslipidemia - Pipeline by InStar Technologies AS, H2 2017
  • Dyslipidemia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by JW Pharmaceutical Corp, H2 2017
  • Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Kowa Company Ltd, H2 2017
  • Dyslipidemia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Lipicard Technologies Ltd, H2 2017
  • Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H2 2017
  • Dyslipidemia - Pipeline by LipimetiX Development Inc, H2 2017
  • Dyslipidemia - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Nippon Chemiphar Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Omeros Corp, H2 2017
  • Dyslipidemia - Pipeline by Pfizer Inc, H2 2017
  • Dyslipidemia - Pipeline by Pharmena SA, H2 2017
  • Dyslipidemia - Pipeline by Protalix BioTherapeutics Inc, H2 2017
  • Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Dyslipidemia - Pipeline by Samjin Pharm Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Sancilio & Company Inc, H2 2017
  • Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Dyslipidemia - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
  • Dyslipidemia - Pipeline by Torrent Pharmaceuticals Ltd, H2 2017
  • Dyslipidemia - Pipeline by Viking Therapeutics Inc, H2 2017
  • Dyslipidemia - Pipeline by Yuhan Corp, H2 2017
  • Dyslipidemia - Dormant Projects, H2 2017
  • Dyslipidemia - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Dyslipidemia - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Dyslipidemia - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Dyslipidemia - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Dyslipidemia - Dormant Projects, H2 2017 (Contd..5), H2 2017
  • Dyslipidemia - Dormant Projects, H2 2017 (Contd..6), H2 2017
  • Dyslipidemia - Dormant Projects, H2 2017 (Contd..7), H2 2017
  • Dyslipidemia - Dormant Projects, H2 2017 (Contd..8), H2 2017
  • Dyslipidemia - Discontinued Products, H2 2017
  • Dyslipidemia - Discontinued Products, H2 2017 (Contd..1), H2 2017
  • Dyslipidemia - Discontinued Products, H2 2017 (Contd..2), H2 2017
  • Dyslipidemia - Discontinued Products, H2 2017 (Contd..3), H2 2017

List of Figures

  • Number of Products under Development for Dyslipidemia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top